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-Syntrophin is a scaffolding adapter protein expressed
primarily on the sarcolemma of skeletal muscle. The
 
COOH-terminal half of 
 
 
 
-syntrophin binds to dystrophin
and related proteins, leaving the PSD-95, discs-large, ZO-1
 
(
 
PDZ) domain free to recruit other proteins to the dystrophin
complex. We investigated the function of the PDZ domain
 
of 
 
 
 
-syntrophin in vivo by generating transgenic mouse lines
expressing full-length 
 
 
 
-syntrophin or a mutated 
 
 
 
-syntrophin
lacking the PDZ domain (
 
 
 
PDZ). The 
 
 
 
PDZ 
 
 
 
-syntrophin
 
displaced endogenous 
 
 
 
- and 
 
 
 
1-syntrophin from the
sarcolemma and resulted in sarcolemma containing little
 
or no syntrophin PDZ domain. As a consequence, neuronal
nitric oxide synthase (nNOS) and aquaporin-4 were absent
 
 
from the sarcolemma. However, the sarcolemmal expression
and distribution of muscle sodium channels, which bind
the 
 
 
 
-syntrophin PDZ domain in vitro, were not altered.
 
Both transgenic mouse lines were bred with an
 
  
 
-syntrophin–
 
null mouse which lacks sarcolemmal nNOS and aquaporin-4.
 
The full-length 
 
 
 
-syntrophin, not the 
 
 
 
PDZ form, rees-
tablished nNOS and aquaporin-4 at the sarcolemma of
these mice. Genetic crosses with the mdx mouse showed
that neither transgenic syntrophin could associate with the
sarcolemma in the absence of dystrophin. Together, these
 
data show that the sarcolemmal localization of nNOS
and aquaporin-4 in vivo depends on the presence of a
dystrophin-bound 
 
 
 
-syntrophin PDZ domain.
 
Introduction
 
The syntrophins are a family of scaffolding proteins that
contain multiple protein interaction domains (Froehner et
al., 1987). All five syntrophins, 
 
 
 
, 
 
 
 
1, 
 
 
 
2, 
 
 
 
1, and 
 
 
 
2, con-
tain two pleckstrin homology (PH)* domains, a PSD-95,
 
discs-large, ZO-1 
 
(
 
PDZ) domain, and a syntrophin-unique
(SU) COOH-terminal region (Ahn et al., 1994; Adams et
al., 1995; Piluso et al., 2000). Using these protein interac-
tion domains, syntrophins are capable of binding multiple
proteins simultaneously to form functional complexes.
Interest in the syntrophins was originally prompted by the
observation that syntrophin was associated with dystrophin
and other members of the dystrophin protein family, includ-
ing utrophin and dystrobrevin (Butler et al., 1992, Ahn and
Kunkel, 1995, Dwyer and Froehner, 1995, Yang et al.,
1995). Mutations in the dystrophin gene lead to Duchenne
and Becker muscular dystrophies (Hoffman et al., 1987).
Syntrophins bind to two sites located in the COOH-termi-
nal region of dystrophin such that two syntrophins can at-
tach to one dystrophin (Newey et al., 2000). Dystrophin
also binds to dystrobrevin, a protein-containing sequence
homology with dystrophin (Sadoulet-Puccio et al., 1996;
Peters et al., 1998) and which can also bind two syntrophins
(Newey et al., 2000). Thus, the dystrophin complex can
bind up to four syntrophins, providing a scaffold for multi-
ple functionally interdependent signaling proteins.
 
 
 
-Syntrophin is the predominant syntrophin isoform in
skeletal and cardiac muscle. In skeletal muscle, 
 
 
 
-syntrophin
is present on the sarcolemma of all fibers, whereas 
 
 
 
1-syn-
trophin is present on the sarcolemma of only fast type II fi-
bers (Peters et al., 1997). Skeletal muscle 
 
 
 
2-syntrophin is
found at high levels only at the postsynaptic membrane of
the neuromuscular junctions (Peters et al., 1994; Kramarcy
and Sealock, 2000). 
 
 
 
2-Syntrophin is also found in skeletal
muscle where it has been reported to be located at the sarco-
lemma (Piluso et al., 2000).
 
Address correspondence to Stanley Froehner, Department of Physiology
and Biophysics, University of Washington, Seattle, WA 98195-7290. Tel.:
 
(206) 543-0950. Fax: (206) 685-0619. E-mail
 
: 
 
froehner@u.washington.edu
 
H. Mueller’s present address is Department of Microbiology and Immu-
nology, University of North Carolina at Chapel Hill, Chapel Hill, NC
27599.
*Abbreviations used in this paper: Ab, antibody; HA, hemagglutinin;
nNOS, neuronal nitric oxide synthase; PDZ, PSD-95, discs-large, ZO-1;
PH, pleckstrin homology; SU, syntrophin unique region.
Key words: syntrophin; aquaporin; dystrophin complex; neuronal nitric
oxide synthase; PDZ domain 
114 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 1, 2001
 
The second PH domain and the highly conserved SU
domain are required for interaction with dystrophin (Ahn
and Kunkel, 1995; Kachinsky et al., 1999). This leaves the
NH
 
2
 
-terminal PH domain and its embedded PDZ domain
free to interact with other ligands and thereby link them to
the dystrophin complex. Indeed, several molecules have
been shown to bind these domains. The NH
 
2
 
-terminal PH
domain can bind to phosphatidyl inositol-4,5-bisphos-
phate (Chockalingam et al., 1999). In vitro biochemical
experiments have shown that the PDZ domain of 
 
 
 
-syn-
trophin can bind to neuronal nitric oxide synthase (nNOS)
(Brenman et al., 1996), muscle voltage-activated sodium
channels (Gee et al., 1998a; Schultz et al., 1998), and
stress-activated protein kinase-3 (Hasegawa et al., 1999).
The 
 
 
 
2-syntrophin PDZ domain binds to microtubule-
associated serine/threonine kinase, and the related syntro-
phin-associated serine/threonine kinase (Lumeng et al.,
1999). Diacylglycerol kinase 
 
 
 
 associates with the PDZ do-
main of 
 
 
 
1-syntrophin (Hogan et al., 2001). Discovery of
these interactions has led to the proposal that syntrophins’
function is to link signaling molecules to the dystrophin
protein complex.
Generation and characterization of 
 
 
 
-syntrophin–null
mice have further strengthened this conclusion. Although
the absence of 
 
 
 
-syntrophin does not result in discernable
musclular dystrophy (Kameya et al., 1999; Adams et al.,
2000), the neuromuscular junctions of these mice are struc-
turally aberrant, have reduced levels of acetylcholine recep-
tors and acetylcholine esterase, and are missing utrophin, an
ortholog of dystrophin (Adams et al., 2000). Furthermore,
nNOS is lost from the sarcolemma in these mice, perhaps
due to the absence of the syntrophin PDZ domain.
In addition to nNOS, the water channel, aquaporin-4,
also shows dependence on 
 
 
 
-syntrophin for sarcolemmal lo-
calization. Aquaporin-4 is absent from the sarcolemma when
 
 
 
-syntrophin is missing either due to the loss of the entire
dystrophin complex in the mdx mouse (Frigeri et al., 1998)
or specific loss of 
 
 
 
-syntrophin by targeted gene disruption
(Yokota et al., 2000). Aquaporins are responsible for the
high membrane permeability of water in many different tis-
sues, including kidney, brain, and the gastrointestinal tract
(Frigeri et al., 1995). Aquaporin-4 is an integral membrane
protein present in the sarcolemma of fast twitch fibers, al-
though its physiological role in muscle is unknown. The
COOH terminus of aquaporin-4 contains a likely PDZ do-
main interaction sequence, -VLSSV. However, this sequence
is not one that we would expect a priori to bind syntrophin
PDZs based on the published consensus binding sequences
(Gee et al., 1998a, 1998b). Thus, the functional relationship
between the 
 
 
 
-syntrophin PDZ domain and sarcolemmal
aquaporin-4 expression is unknown.
PDZ domains are involved in the assembly of macromo-
lecular complexes at numerous sites of membrane specializa-
tion. These specializations include the neuromuscular syn-
apse (Adams et al., 2000), synapses between neurons in the
brain (Sheng, 1996; Kornau et al., 1997), the apical and ba-
soloateral membranes of polarized epithelia (Short et al.,
1998; Kachinsky et al., 1999), and receptor-dense areas that
induce apoptosis in tumor cells (Yanagisawa et al., 1997).
The most common mode of interaction is between the
COOH-terminal tail of ligand and the PDZ domain (Doyle
et al., 1996), although association with internal PDZ bind-
ing sequences and PDZ-PDZ heterodimerization also oc-
curs (Gee et al., 1998b; Hillier et al., 1999; Tochio et al.,
Figure 1.  Construction and characterization of 
transgenic mice. (A) The mouse cDNA sequence 
of full-length  -syntrophin and  -syntrophin 
missing the PDZ domain ( PDZ) was placed 
downstream of the mouse muscle creatine kinase 
(MCK) promoter and the VP1 intron of plasmid 
pCKVA. The PDZ domain of the Tg  PDZ 
construct was replaced with an HA tag. The bind-
ing sites for mAb 1351 and Ab SYN 17 are shown. 
(B) Expression of transgene products was examined 
by immunoblotting. 20  g (wild-type control) and 
2  g (transgenics) of total protein isolated from 
skeletal muscle were subjected to immunoblot 
analysis. SYN17 recognizes both endogenous and 
transgenic  -syntrophin; mAb 1351 recognizes 
endogenous and Tg  -Syn but not Tg  PDZ; HA 
recognizes only Tg  PDZ. Very small amounts of 
endogenous  -syntrophin can be seen in the Tg 
 PDZ preparations with SYN17 and mAb 1351. 
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2000). Despite the fact that PDZ proteins have been studied
extensively and the structure is known in great detail (Hillier
et al., 1999), the PDZ–ligand interactions have not been
characterized in vivo. An in vivo demonstration is important
for two reasons. First, other interactions have been proposed
to play a role in the localization of nNOS to the membrane
by 
 
 
 
-syntrophin. (Venema et al., 1997; Abdelmoity et al.,
2000). The relative importance of these multiple binding
sites has yet to be determined. Second, and perhaps more
important, the large number of PDZ-containing proteins
and potential binding proteins undoubtedly requires a level
of specificity that extends beyond that achieved by the
amino acid sequence adjacent to the terminal S-X-V motif.
We observed such specificity with the PDZ domain of 
 
 
 
1-
syntrophin that can bind nNOS in vitro (Gee et al., 1998a),
but that is unable to recruit nNOS to the sarcolemma in
vivo in the absence of 
 
 
 
-syntrophin (Adams et al., 2000).
The development of in vivo systems for the study of this and
similar phenomena will be very important in understanding
how specificity of the formation of the complexes is gov-
erned, and to what extent the interactions found in vitro ac-
tually exist in the cell.
These issues have prompted us to develop mouse models
to test the function of the 
 
 
 
-syntrophin PDZ interactions in
vivo. We have developed lines of transgenic mice that ex-
press a form of 
 
 
 
-syntrophin in which the PDZ domain has
been replaced with an epitope tag. We have used this trans-
genic line in combination with one expressing full-length
 
 
 
-syntrophin in dominant negative and genetic rescue
experiments. These new mouse models demonstrate that
nNOS and aquaporin-4, but not sodium channels, require
the presence of an 
 
 
 
-syntrophin PDZ domain for sarcolem-
mal localization in vivo. Furthermore, 
 
 
 
-syntrophin requires
the presence of the dystrophin complex to form a stable as-
sociation with the sarcolemma.
 
Results
 
In vitro experiments have shown that the PDZ domain of
 
 
 
-syntrophin can associate with the sarcolemmal proteins
nNOS (Brenman et al., 1996) and the voltage gated sodium
channels, SCN4A and SCN5A (Gee et al., 1998a; Schultz et
al., 1998). To address the role of the syntrophin PDZ do-
main in vivo, we developed transgenic mice expressing a
modified 
 
 
 
-syntrophin lacking the PDZ domain.
 
Generation and characterization of transgenic mice
 
We developed two lines of transgenic mice (Fig. 1). The
first, Tg 
 
 
 
-Syn, expresses full-length 
 
 
 
-syntrophin. The sec-
ond, Tg 
 
 
 
PDZ, expresses an altered form of 
 
 
 
-syntrophin
in which the PDZ domain was replaced with the hemagglu-
tinin (HA) epitope tag. The expression of both proteins is
under control of the mouse muscle creatine kinase pro-
moter; therefore, they are expressed primarily in skeletal and
cardiac muscle. Endogenously produced 
 
 
 
-syntrophin can
be differentiated from the 
 
 
 
PDZ transgene product by the
Figure 2.  Comparative localization of 
 -syntrophin in control and transgenic 
mice. Immunofluorescence microscopy 
of adult ( 8 wk) mouse quadriceps mus-
cle shows that the HA-tagged Tg  PDZ 
transgene product is localized at the 
sarcolemma. Labeling with mAb 1351 is 
strong on normal and Tg  -Syn muscle 
but shows greatly reduced intensity in 
the Tg  PDZ muscle. Thus, Tg  PDZ 
syntrophin displaces the endogenous 
 -syntrophin. Antibody SYN17 that 
recognizes both transgene products and 
endogenous  -syntrophin shows a modest 
increase in labeling intensity at the 
sarcolemma and in the cytosol in the 
transgenic muscle.  1-Syntrophin is 
displaced by the high expression of the 
Tg  PDZ product but remains present, 
although at reduced levels, in the mus-
cle of the full-length  -syntrophin trans-
genic mouse.  1-Syntrophin is also 
detected in blood vessels surrounding 
muscle fibers in all sections. Bar, 50  m. 
116 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 1, 2001
 
use of a monoclonal antibody (1351) that recognizes an
epitope within the PDZ domain (Materials and methods).
Both transgene products and endogenous 
 
 
 
-syntrophin are
recognized by rabbit polyclonal antibody, SYN17, as the an-
tibody was made to a peptide sequence that lies just down-
stream of the PDZ domain. Immunoblot analysis using
these antibodies shows that proteins derived from the trans-
genes are expressed at levels 20–30-fold higher than endoge-
nous 
 
 
 
-syntrophin in skeletal muscle (Fig. 1 B).
We characterized the distribution of the transgene prod-
ucts within muscle by immunofluorescence (Fig. 2). Mouse
quadriceps muscle was labeled using the same set of antibod-
ies used for the Western blots in Fig. 1. Labeling with the
anti-HA antibody shows that the 
 
 
 
PDZ transgene product
accumulates on the sarcolemma. Cytosolic labeling can be
seen for both transgene products and is most likely due to
the high levels of expression of these proteins, which cannot
be accommodated by the available membrane binding sites.
Figure 3.  Association of the Tg  PDZ product with 
dystrophin. Dystrophin and associated proteins were 
immunoprecipitated from wild-type (C57) and Tg 
 PDZ skeletal muscle (Dys). Control samples were 
prepared by substituting normal mouse IgG for the 
dystrophin antibody (IgG). (A) Immunoblotting with 
the HA antibody shows that the transgene product 
copurifies with dystrophin. (B) Immunoblotting with 
SYN17 confirms that the Tg  PDZ product displaces 
endogenous syntrophin from the dystrophin complex 
(no 58-kD band, corresponding to the full-length 
endogenous  -syntrophin, is seen in the Tg  PDZ lane).
Figure 4.  Immunofluorescence analysis of syntrophin-associated proteins in mouse quadriceps muscle. In the absence of the  -syntrophin 
PDZ domain (Tg  PDZ) or dystrophin (mdx), nNOS and aquaporin-4 fail to localize at the sarcolemma while sodium channel (NaCh) distribution 
appears unchanged. Dystrophin levels appear normal in the transgenic animals. Note: the dystrophin-labeled fiber in the mdx mouse is prob-
ably a revertant fiber and serves as a convenient focussing and antibody control. Bar, 50  m. 
 
 
-Syntrophin PDZ domain localizes nNOS and AQP4 |
 
 Adams et al. 117
 
Labeling with antibody 1351 is greatly reduced in the Tg
 
 
 
PDZ muscle (Fig. 2). Sarcolemmal labeling is faint or ab-
sent (Fig. 2) although neuromuscular junctions remain
brightly labeled (unpublished data). These results indicate
that the endogenous 
 
 
 
-syntrophin is displaced from the sar-
colemma by the high levels of  PDZ-syntrophin.
Tg  PDZ protein also displaces  1-syntrophin (Fig. 2).
Sarcolemmal labeling for  1-syntrophin is greatly reduced
in the Tg  PDZ muscle, but neighboring blood vessels,
where the transgene is not expressed, show normal high lev-
els of expression. The Tg  -Syn protein does not displace
 1-syntrophin to the same extent as the Tg- PDZ protein,
despite being expressed at somewhat higher levels (Fig 1 B).
Sarcolemmal levels of  1-syntrophin are reduced in the
muscles of the Tg  -Syn mice, but are still clearly present
and even brightly labeled on the smaller fibers. These small
fibers may represent areas of immature muscle.  1-Syntro-
phin is expressed in most skeletal muscle fibers during the
first six weeks of mouse muscle development after which its
sarcolemma levels decline in all but the fast type II fibers
(Kramarcy and Sealock, 2000). Other than having a higher
number of small fibers, muscles of the transgenic mice did
not show any of the abnormalities commonly found in dys-
trophic muscle (central nuclei, split fibers, fibrosis, etc.).
Association of transgenic syntrophins with dystrophin
Syntrophin associates with the sarcolemma by binding di-
rectly to dystrophin and dystrobrevin (Ahn and Kunkel,
1995, Dwyer and Froehner, 1995, Yang et al., 1995; Newey
et al., 2000). To determine if the transgenic syntrophins Tg
 PDZ and Tg  -Syn bound dystrophin, we isolated the
dystrophin complex from muscle homogenates by immuno-
precipitation with anti-dystrophin antibody. Immunoblot-
ting of the complexes with anti-HA antibody showed that
the Tg  PDZ protein copurified with dystrophin (Fig. 3).
Similar blotting with SYN17 confirmed the presence of Tg
 PDZ and also showed that Tg  -Syn copurified with dys-
trophin as expected (Fig. 3). We consistently observed pro-
portionally more Tg  PDZ than either the endogenous or
transgenic full-length syntrophin in the dystrophin isolates
(Fig. 3), suggesting that the Tg  PDZ syntrophin may have
a higher affinity for dystrophin than the full-length forms.
This conclusion is consistent with the immunofluorescence
data (Fig. 2) showing that Tg  PDZ syntrophin displaced
 1-syntrophin to a greater extent than did Tg  -Syn.
Distribution of syntrophin PDZ ligands in transgenic 
skeletal muscle
Having shown that the Tg  PDZ syntrophin displaces en-
dogenous  - and  1-syntrophin, we examined how the ab-
sence of a sarcolemmal syntrophin PDZ domain affected the
distribution of PDZ ligands. The distributions of nNOS,
sodium channels, and aquaporin-4 were examined by im-
munofluorescence microscopy (Fig. 4). In the absence of
a sarcolemmal  -syntrophin PDZ domain, nNOS is no
longer present on the sarcolemma. Thus, the syntrophin
PDZ domain is necessary for localization of nNOS to the
sarcolemma in a stable manner.
In wild-type skeletal muscle, nNOS resides both in the cy-
tosol and at the sarcolemma where it is linked to the cyto-
skeleton via the syntrophin/dystrophin complex. To con-
firm the immunofluorescence data, we determined the
relative levels of nNOS in the soluble (cytosolic) and deter-
gent-soluble (membrane associated) fractions of mouse mus-
cle (Fig. 5). In both wild-type and Tg  -Syn mice, nNOS
was present in both fractions. However, in samples from Tg
 PDZ mice, nNOS was present only in the soluble fraction
supporting the conclusion that the sarcolemmal localization
of nNOS requires the  -syntrophin PDZ domain.
Previous reports have implicated the dystrophin complex
(Frigeri et al., 1998) and  -syntrophin (Yokota et al.,
2000) in the expression of aquaporin-4 at the plasma
membrane of fast twitch muscle. To determine the impor-
tance of the PDZ domain in aquaporin-4 sarcolemmal ex-
pression, we examined the distribution of aquaporin-4 in
the   -syntrophin transgenic mice. As shown in Fig. 4,
aquaporin-4 is no longer present at the sarcolemma in the
absence of a syntrophin PDZ domain. The loss of sar-
colemmal aquaporin-4 occurs even though the distribution
of dystrophin is unaffected in the transgenic mice (Fig. 4).
Unlike nNOS, which associates peripherally with the sar-
colemma, aquaporin-4 is an integral membrane protein. Its
absence from the sarcolemma of Tg  PDZ mouse muscle
implies that syntrophin must function to target or stabilize
aquaporin-4 in muscle. Conversely, the absence of a syn-
trophin PDZ domain had no apparent affect on the distri-
bution or level of expression of voltage gated sodium chan-
nels in muscle (Fig. 4).
PDZ ligand restoration in
syntrophin-null/transgenic crosses
In genetically modified mice lacking  -syntrophin, nNOS
is absent from the sarcolemma (Kameya et al., 1999; Ad-
ams et al., 2000). This has been assumed to be due to the
loss of the  -syntrophin PDZ domain. We tested this as-
sumption directly by breeding the two syntrophin trans-
genic mice lines onto the  -syntrophin–null background.
Immunofluorescence studies show that the sarcolemmal lo-
calization of nNOS is “rescued” by the full-length syntro-
phin transgene but not by the  PDZ transgene (Fig. 6).
Thus, in vivo, nNOS localization to the sarcolemma de-
pends on the presence of an  -syntrophin PDZ domain.
Similarly, aquaporin-4, normally absent from the sarco-
lemma of  -syntrophin–null mice, was restored by the full-
length transgene but not by the  PDZ construct (Fig. 6).
Our attempts to show in vitro that the aquaporin-4
Figure 5.  nNOS is shifted from cytoskeletal association to the 
soluble pool in the Tg  PDZ muscle. Samples from soluble cytosolic 
(S) or 1% Triton (T) skeletal muscle extracts were analyzed for 
nNOS by immunoblotting. In the absence of the  -syntrophin PDZ 
domain, nNOS is found only in the soluble fraction. High levels of 
expression of full-length  -syntrophin do not change the relative 
amounts of nNOS in the cytosolic and insoluble fractions.118 The Journal of Cell Biology | Volume 155, Number 1, 2001
COOH-terminal sequence binds directly to  -syntrophin
have been unsuccessful, even under conditions in which a
similar peptide corresponding to the COOH terminus of
the sodium channel binds robustly (unpublished data).
Nevertheless, these in vivo data clearly show that sarcolem-
mal localization of aquaporin-4 requires the  -syntrophin
PDZ domain.
Syntrophin transgene localization in
dystrophin-deficient muscle
Both the Tg  PDZ and the Tg  -Syn mouse lines were bred
with the mdx mice to produce mice overexpressing syntro-
phin in the absence of dystrophin. Immunofluorescence
analysis of the muscles of these mice showed that despite be-
ing expressed at high levels (Fig. 7 A), neither protein associ-
ated with the sarcolemma in the absence of dystrophin (Fig.
7 B). Histologically, the Tg  PDZ/mdx and the Tg  -Syn/
mdx muscles were indistinguishable from mdx controls (un-
published data). It is noteworthy that even though low levels
of utrophin are expressed on the mdx sarcolemma, we did
not detect sarcolemmal  -syntrophin (Fig. 7). Thus,  -syn-
trophin may have a relatively low affinity for utrophin, con-
sistent with previous immunoisolation experiments (Peters
et al., 1997). The PH domain association with phosphatidyl
inositol-4,5-bisphosphate (Chockalingam et al., 1999) and
the PDZ domain association with the COOH-terminal tail
of sodium channels (Gee et al., 1998a; Schultz et al., 1998)
are apparently insufficient to recruit  -syntrophin to the sar-
colemma in the absence of dystrophin.
Discussion
The role of PDZ domain proteins in targeting, anchoring,
and stabilizing membrane channels and receptors has been
investigated using a variety of approaches such as peptide
overlays, yeast two-hybrid assays, surface plasmon reso-
nance, and cell transfection experiments. Many PDZ-ligand
interactions have been well characterized in vitro, including
AMPA receptors, which interact with the PDZ domain pro-
teins GRIP (Dong et al., 1997) and PICK-1 (Xia et al.,
1999); the cystic fibrosis transmembrane receptor, which
binds the PDZ domain proteins CAP-70 (CFTR-associated
protein, 70 kDA) (Wang et al., 2000) and the Na
 /H
  ex-
changer regulatory factor (Raghuram et al., 2001); and the
PDZ domains of postsynaptic density protein-95 and other
members of the MAGUK family of proteins, which bind to
NMDA receptor (Kornau et al., 1995) and to nNOS (Bren-
man et al., 1996). However, recent findings from our lab
suggest that at least in some cases PDZ-ligand interactions
that occur in vitro may not occur in vivo. The PDZ do-
mains of  ,  1, and  2 syntrophin have been shown to bind
nNOS with similar affinity in vitro (Gee et al., 1998b), but
in skeletal muscle of the  -syntrophin–null mouse  1 and
 2 syntrophin do not associate with nNOS (Adams et al.,
2000). The demonstration of in vivo specificity of PDZ do-
mains has prompted us to use in vivo approaches to investi-
gate the physiological relevance of PDZ domain/ligand in-
teractions.
Some PDZ-ligands have been characterized in vivo using
invertebrate models. In Caenorhabditis elegans, three PDZ
Figure 6.  Sarcolemmal expression of nNOS and aquaporin-4 in genetic crosses of  -syntrophin–null mice with transgenic mice. Both 
nNOS and aquaporin-4 are absent from the sarcolemma of  -syntrophin–null mice. Muscle from  -syntrophin–null mice crossed with Tg 
 -Syn mice shows sarcolemmal expression of both nNOS and aquaporin-4. Sarcolemmal expression of these proteins is not restored in 
muscle of  -syntrophin–null mice crossed with Tg  PDZ mice. Bar, 50  m. -Syntrophin PDZ domain localizes nNOS and AQP4 | Adams et al. 119
proteins, Lin-2, Lin-7, and Lin-10, mediate the localization
of the LET-23 receptor (Kaech et al., 1998). This receptor
fails to localize to the basolateral surface when the PDZ pro-
teins are mutated. Mutational studies in Drosophila show
that the PDZ domain–containing protein, discs large, is re-
quired for the neuromuscular junction localization of Shaker
potassium channels (Tejedor et al., 1997). However, no di-
rect test of PDZ-ligand interactions has been reported in
whole animal mammalian systems. In this paper, we have
described one approach that should be generally applicable
to in vivo analyses in a broad range of systems.
We investigated the functional role of the  -syntrophin
PDZ domain in vivo by using a dominant-negative ap-
proach. We developed a transgenic mouse line that expresses
a PDZ-less form of  -syntrophin at high levels in skeletal
muscle. The observation that  PDZ  -syntrophin is local-
ized to the sarcolemma indicates that the PDZ domain is
not required for plasma membrane association. This result is
consistent with the demonstration that the PH2 and SU do-
mains in tandem are required for binding to dystrophin and
other family members (Ahn and Kunkel, 1995; Kachinsky et
al., 1999). Furthermore, the  PDZ form of  -syntrophin
competed with endogenous  -syntrophin for binding sites
on the sarcolemma (dystrophin and dystrobrevin). This
competition produced skeletal muscle that contained little
or no sarcolemmal syntrophin PDZ domain as demon-
strated by the reduction in labeling with mAb 1351, an anti-
body that binds to an epitope within the PDZ domain of
 -syntrophin.
In addition to displacing endogenous  -syntrophin, the
 PDZ   -syntrophin was able to displace  1-syntrophin
from the sarcolemma as well. These data suggest that  - and
 1-syntrophin compete for the same binding sites, at least
under conditions of high  -syntrophin expression, to facili-
tate membrane association. Interestingly, the  PDZ form
was more effective than the full-length Tg  -syntrophin in
displacing  1-syntrophin. This suggests that the absence of
the PDZ domain increases the affinity of syntrophin for dys-
trophin/dystrobrevin. Thus, the PDZ domain of syntrophin
may act to regulate the interaction of syntrophin with the
dystrophin complex. An interesting possibility is that bind-
ing of a ligand to the PDZ domain promotes association of
Figure 7.  Distribution of Tg  PDZ and Tg  -Syn in the absence of dystrophin. (A) Both Tg  PDZ and Tg  -Syn proteins (detected with 
SYN17) are expressed at high levels in muscle lacking dystrophin (mdx/Tg  PDZ and mdx/Tg  -Syn). (B) Despite high levels of transgene 
product expression, neither the full-length nor the Tg  PDZ syntrophin are found on the sarcolemma. Utrophin sarcolemmal expression is 
upregulated in the mdx mouse but apparently to levels insufficient to recruit  -syntrophin. Bar, 50  m.120 The Journal of Cell Biology | Volume 155, Number 1, 2001
the PH-SU domains with their binding sites on dystrophin.
Such regulation is similar to that demonstrated for MAGUK
family proteins (McGee and Bredt, 1999) and could be im-
portant for localizing PDZ ligands to the sarcolemma via the
dystrophin complex.
Two syntrophin PDZ ligands have been studied exten-
sively in vitro. nNOS and voltage-gated sodium channels
bind to  -syntrophin PDZ domains but via different mech-
anisms. nNOS contains a beta-finger immediately adjacent
to its own PDZ domain that interacts directly with the PDZ
domain of syntrophin (Hillier et al., 1999). In contrast, so-
dium channels bind to syntrophin PDZ domains via the
more conventional COOH terminal “SXV” motif (Gee et
al., 1998a). The function of this interaction is unknown, but
syntrophin binding could potentially affect the ion conduc-
tion properties of the sodium channel or mediate its partici-
pation in a scaffold involving other channels and/or modify-
ing enzymes. However, our data show that syntrophin
binding is not required for normal sodium channel distribu-
tion on the sarcolemma. This conclusion is in agreement
with the observation that sodium channel density is only
slightly reduced in skeletal muscle of the mdx mouse which
lacks dystrophin and, therefore, sarcolemmal syntrophin
(Ribaux et al., 2001).
In contrast, sarcolemmal localization of nNOS does de-
pend on the presence of an  -syntrophin PDZ domain. In
the absence of a sarcolemmal syntrophin PDZ domain,
nNOS fails to localize to the sarcolemma. The localization
of nNOS to the sarcolemma is important in regulat-
ing blood flow in skeletal muscle during muscle activity.
Thomas et al. (1998) have shown that in the absence of
nNOS, attenuation of adrenergically stimulated vasocon-
striction does not occur. Similar results were obtained from
mdx mice which lack sarcolemmal nNOS (Thomas et al.,
1998). Therefore, it is likely that the  -syntrophin PDZ do-
main is not only necessary for proper localization of nNOS
but is required for proper function of nNOS in skeletal mus-
cle as well.
In addition to syntrophin, another membrane-associated
protein, caveolin-3, has been shown to bind nNOS (Ven-
ema et al., 1997). However, in muscle from the Tg  PDZ
mice and the Tg  PDZ/  -syntrophin–null cross, we could
not detect nNOS on the membrane. Therefore, the interac-
tion of nNOS with caveolin-3 must be insufficient for stable
retention of nNOS at the sarcolemma. It has also been pro-
posed that nNOS may localize to the sarcolemma by bind-
ing membrane-associated proteins directly via its PDZ do-
main (Abdelmoity et al., 2000). Because in the absence of a
syntrophin PDZ domain we do not detect nNOS on the
sarcolemma, if such interactions occur they are insufficient
for stable retention. Alternatively, such interactions could be
induced by association of the nNOS beta finger with the
syntrophin PDZ domain.
A third putative ligand for the  -syntrophin PDZ domain
is aquaporin-4. Aquaporin-4 is normally present on the sar-
colemma of fast twitch fibers of skeletal muscle but is absent
from muscle that lacks the dystrophin protein complex
(Frigeri et al., 1998). The COOH-terminal amino acid se-
quence of aquaporin-4 is -VLSSV, a potential class I PDZ
domain interaction sequence. Therefore, we used our trans-
genic mice to determine if the membrane localization of
aquaporin-4 depended on a syntrophin PDZ domain. In the
absence of an  -syntrophin PDZ domain, aquaporin-4 is
also absent from the sarcolemma. Aquaporin-4 is an integral
membrane protein that contains six transmembrane do-
mains and therefore does not need to be recruited to the sar-
colemma like the soluble protein, nNOS. Rather, the syn-
trophin PDZ domain is likely involved in targeting or
stabilizing aquaporin-4.
The in vivo studies presented here also provide insight
into how  -syntrophin interacts with the sarcolemma. Data
from the Tg  PDZ show that  -syntrophin is localized to
the sarcolemma and binds directly to dystrophin in the ab-
sence of a PDZ domain. However, the immunofluorescence
studies of muscle expressing full-length and  PDZ syntro-
phin on an mdx background show that, even when ex-
pressed at high levels, syntrophin does not associate with the
sarcolemma in the absence of dystrophin. Apparently, inter-
actions with sodium channels or phosphatidyl inositols are
insufficient to localize syntrophin to the sarcolemma. In
fact, our data indicate that interaction with the dystrophin
complex is necessary and sufficient for sarcolemmal  -syn-
trophin localization.
Materials and methods
Generation of transgenic mice
We have previously isolated and characterized the mouse cDNA encoding
 -syntrophin (Adams et al., 1993). This cDNA was modified by excising
nucleotides 332–622 with restriction enzymes Ec47 and EcoRI (New En-
gland Biolabs) to remove the sequence encoding 98 amino acids of the
PDZ domain. Excised sequence was replaced with a double stranded syn-
thetic oligonucleotide (Macromolecular Resources) encoding the HA
epitope. The resulting construct, designated  PDZ, and the full-length
 -syntrophin cDNA were cloned into the SacII site of vector pCKVA (Cox
et al., 1993), a gift from Jeff Chamberlain (University of Washington, Seat-
tle, WA). The pCKVA vector contains 3,300 bp of the mouse muscle crea-
tine kinase promoter, a 700-bp viral intron, and a 200-bp poly-A signal
sequence. The linearized constructs were injected into C57Bl6 oocytes
(University of North Carolina Transgenic Facility, Chapel Hill, NC). Three
independent lines of mice harboring the  PDZ construct (Tg  PDZ) and
nine lines of mice harboring the full-length construct (Tg  -Syn) were iden-
tified by Southern blotting and PCR.
Mice expressing Tg  PDZ and mice expressing Tg  -Syn were bred onto
an  -syntrophin–null background by crossing with the previously charac-
terized  -syntrophin–null mice (Adams et al., 2000). Similarly, the trans-
genic lines were bred onto the mdx background. In each case the geno-
types were confirmed by PCR of genomic DNA derived from tail biopsies.
Antibodies
Isoform specific rabbit polyclonal antibodies SYN17 ( -syntrophin) and
SYN37 ( 1-syntrophin) have been previously characterized (Peters et al.,
1997). The polyclonal anti-HA antibody was purchased from Zymed Labo-
ratories, Inc. For detection of nNOS, two antibodies were used: an mAb
from BD Transduction Laboratories (San Diego, CA) was used for Western
blots, and a polyclonal antibody (Ab) from Diasorin (Stillwater, MN) was
used for immunofluorescence microscopy. The polyclonal Ab to aqua-
porin-4 was purchased from Chemicon. The polyclonal Ab recognizing
both the SCN4A and SCN5A isoforms of the sodium channel was a gift
from S. Rock Levinson, (University of Colorado Health Sciences Center,
Denver, CO). The utrophin polyclonal Ab was raised against a peptide at
the COOH terminus identical to that previously described for Ab 1862
(Kramarcy et al., 1994). The mAb Mandra 1, recognizing dystrophin, was
purchased from Sigma-Aldrich.
We have previously described mAb 1351 (Froehner et al., 1987) and
have shown that it recognizes an epitope within the PDZ domain of  -,
 1-, and  2-syntrophin (Gee et al., 1998a). However, for this study it was
important to identify the epitope more specifically. Therefore, we synthe-
sized 29 overlapping peptides of 13 amino acids each that spanned the en- -Syntrophin PDZ domain localizes nNOS and AQP4 | Adams et al. 121
tire PDZ domain of  -syntrophin (SPOTs blot; Genosys). Incubation of
mAb 1351 with these peptides using the protocol supplied by the manu-
facturer showed that the epitope is confined to a 13–amino acid segment
with the sequence: ISKIFKGLAADQT. This sequence corresponds to
amino acids 108–120 within the  -syntrophin PDZ domain.
Immunoblotting
Muscle protein detergent extracts were prepared as previously described
(Peters et al., 1997). Dystrophin was isolated by incubating muscle extracts
with the dystrophin mAb Mandra-1 followed by precipitation with protein
G–coated beads (Sigma-Aldrich). After washing the beads three times with
phosphate buffered saline (10 mM sodium phosphate, 150 mM sodium
chloride, pH 7.4), we resuspended the specifically bound protein in SDS-
PAGE sample buffer. Protein samples were subjected to electrophoresis on
an 8% polyacrylamide tricine-buffered gel. Separated proteins were trans-
ferred to Immobilon-P membrane (Millipore Corp.) and incubated with the
indicated antibody as previously described (Peters et al., 1997). Bands
were visualized using a peroxidase-conjugated secondary antibody (Jack-
son ImmunoResearch Laboratories) and a luminol-based substrate (Pierce
Chemical Co.).
Fluorescence microscopy
Immunofluorescence labeling was performed on unfixed muscle flash fro-
zen in liquid nitrogen cooled isopentane. 8- m cryosections were incu-
bated with antibody (30 nM IgG, in each case) as described by Peters et al.
(1997). Primary antibodies were visualized using Alexa-488 and -568 (Mo-
lecular Probes) conjugated secondary antibodies. Sections were analyzed
using a Leica TCS NT confocal microscope.
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